On the other hand, decreased levels of NRF2 in SOD1-ALS points to dimethyl fumarate (DMF) [51,52], an inducer of this pathway, as a good therapy for this sub-group of patients. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.